Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 17, 2001

View Archived Issues

GlaxoSmithKline and First Genetic Trust to research adverse drug reactions

Enzo Biochem reports positive phase II data for hepatitis B treatment

ODAC meeting rescheduled for early December

Health Canada approves enhanced labeling for Copaxone

GSK, UCSF and MMV establish collaborative project

Foradil now cleared for use in COPD in the U.S.

First-in-class antibiotic introduced in major European market

Ibex enzyme therapeutics acquired by BioMarin

Introgen obtains exclusive worldwide license for tumor suppressor genes

Development of beraprost for intermittent claudication expected to be dropped

BioVex and AstraZeneca establish gene target validation collaboration

Cilomilast does not affect esophageal motility or gut transit times in man

Gliatech obtains disappointing results from MRI reevaluation of ADCON-L

Minodronate promising as parenteral or oral treatment of tumor-induced osteolysis

Approval of Viread recommended by FDA advisory committee

Combination therapy may have additional benefit in osteoporosis

Promising clinical data for LY-333334 discussed at ASBMR annual meeting

Vernalis makes substantial progress on development projects

Synthetic vitamin D analogue increases bone mass without hypercalcemia in osteoporosis

Experimental acute pancreatitis ameliorated by ET receptor blockade

Researcher at Northwestern discovers second ALS gene

Selective T-type calcium channel blockers discovered by Danish-American team

Aventis isolates new peptides which activate SARCA2

Use of MMP inhibitor compounds for preparation of diagnostic and therapeutic complexes

New antitumor compounds from Sugen interact with protein kinases

Japanese group identifies porphyrin compounds useful in photodynamic therapy of cancer

Lysophosphatidic acid receptor antagonists designed at Kirin Brewery

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...